8 STRONG BUYS
7/8/10 10:11 PM ET
(1) Oxigene - OXGN
Trading near cash. This is the CTIC of 2010-2011, but with better science - VDA's novel mechanism of action. This is a no-brainer while trading at or near $0.30. Potential acquisition target at these levels.
-- 7/15/10: OxiGene: Dirt Cheap, Lots of Potential
-- 7/20/10: A Doc's Take on OxiGene's Ophthalmology Program
SOLD! (2) Cypress Biosciences - CYPB
Trading at or below cash; sales from Fibromyalgia drug growing albeit somewhat slowly.
-- 7/22/10: I issued a formal sell recommendation for January 2011 $2.50 calls - gain of +140%.
-- 8/2/10: RXI member and friend, David Kieve, reported a +200% gain on the January 2011 $2.50 calls.
-- 11/2010: In late November 2010, a formal sell recommedation was [finally] issued for CYPB's common shares.
SOLD! (3) Vanda Pharmaceuticals - VNDA
Trading at or below cash; recently approved drug for CNS disorder (schizophrenia, as I recall).
Shares of VNDA hit my $10 target on 12/21/10. While shares are likely to head higher from here, the position has been Closed at Rx Investors.
(4) Santarus - SNTS
Trading at 4X earnings with pending catalysts in 2010.
SOLD! (5) Genomic Health - GHDX
Diagnostics maker with excellent revenue stream, potential acquisition target
-- 12/2010: In early December 2010, GHDX hit my $20 price target. After an Open Position hits its target, it's Closed.
SOLD! (6) Curis - CRIS
Strong pipeline + the support of Roche-Genentech - RHHBY.
--8/2010: A formal sell recommendation was issued on shares of CRIS at $1.77 for a nominal gain in August 2010.
(7) Infinity Pharmaceuticals - INFI
Strong pipeline, plenty of cash and a revenue stream coming in from collab's.
(8) Spectrum Pharmaceuticals - SPPI
- Zevalin sales continue to grow Q/Q.
- Evidence demand is increasing with new German Zevalin supplier, now drug available 6 days rather than 2 days each week.
- 2011: Fusilev FDA decision scheduled for 4/29/11.
- 2012: Eoquin and Belinostat - the latter two have HUGE potential for bladder cancer and PTCL respectively.
-SPPI remains an acquisition target.
Disclosure: Long SPPI.